Denali Therapeutics Inc

NASDAQ:DNLI   3:59:54 PM EDT
31.47
-0.24 (-0.76%)
Products

Denali Therapeutics Reports New Interim Data From Early-to-Mid Stage Study Of Its Neurological Drug Candidate

Published: 08/31/2022 12:30 GMT
Denali Therapeutics Inc (DNLI) - Denali Therapeutics Announces New Interim Data From Phase 1/2 Study of Dnl310 (etv:ids) in Mps Ii (hunter Syndrome) at Ssiem 2022.
Denali Therapeutics Inc - Safety Profile, Now With Up to 85 Weeks of Dosing, Continues to Be Similar to Standard of Care.
Denali Therapeutics Inc - Phase 2/3 Compass Study is Actively Enrolling.